Restoration of wild‐type conformation and activity of a temperature‐sensitive mutant of p53 (p53V272M) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE‐1
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The aminothiol WR1065, the active metabolite of the cytoprotector amifostine, exerts its antimutagenic effects through free‐radical scavenging and other unknown mechanisms. In an earlier report, we showed that WR1065 activates wild‐type p53 in MCF‐7 cells, leading to p53‐dependent arrest in the G 1 phase of the cell cycle. To determine whether WR1065 activates p53 by modulating protein conformation, we analyzed its effects on p53 conformation and activity in the esophageal cancer cell line TE‐1. This cell line contains a mutation in codon 272 of p53 (p53 V272M, with methionine instead of a valine), conferring temperature‐sensitive properties to the p53 protein. At the nonpermissive temperature (37°C), p53 V272M adopts the mutant p53 conformation (nonreactive with the antibody PAb1620), does not bind specifically to DNA, and is not activated in response to DNA‐damaging treatment. However, treatment with 0.5–4 mM WR1065 partially restored wild‐type conformation at 37°C, stimulated DNA binding activity, and increased the expression of p53 target genes WAF‐1, GADD45, and MDM2, leading to cell‐cycle arrest in G 1. These results suggest that WR1065 activates p53 through a mechanism distinct from DNA‐damage signaling, which involves modulation of p53 protein conformation. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Cited by
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Self-citationTherapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Targeting Oncogenic Mutant p53 for Cancer Therapy
Parrales, A., & Iwakuma, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00288 · Cited by 337
Allele-Specific p53 Mutant Reactivation
Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 319
Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors
Xia, Y., Choi, H.-K., & Lee, K. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.01.033 · Cited by 278
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
“In recent years, a number of molecules that can reactivate mutant p53 have been identified, including short peptides (Selivanova et al., 1997; Issaeva et al., 2003), glycerol (Ohnishi et al., 1999, 2002), ellipticine derivatives (Sugikawa et al., 1999), CP-31398 (Foster et al., 1999), WR1065 (North et al., 2002), and…”
BackgroundReactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186
“WR1065 can at least partially restore wild-type conformation to the temperature-sensitive V272M p53 mutant at 371C, stimulate its DNA binding activity and induce expression of the p53 target genes p21, GADD45 and MDM2, leading to cell-cycle arrest in G1 (North et al., 2002).”
BackgroundIsolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library
Shiraishi, K., Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Sakayori, M., Ishida, T., Takeda, M., Kanamaru, R., Ohuchi, N., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310815200 · Cited by 96
Demir, Ö., Baronio, R., Salehi, F., Wassman, C. D., Hall, L., Hatfield, G. W., Chamberlin, R., Kaiser, P., Lathrop, R. H., & Amaro, R. E. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002238 · Cited by 39
Metadata
- Authors
- North, S., Pluquet, O., Maurici, D., El Ghissassi, F., & Hainaut, P.
- Venue
- Molecular Carcinogenesis
- Publisher
- Wiley
- Published
- 2002-02-20
- Volume
- 33
- Issue
- 3
- Pages
- 181-188
- ISSN
- 0899-1987 (ISSN-L)
- 1098-2744
- OpenAlex
- W2032323614
- Cited by
- 75
- References
- 1
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.